| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Expanded pipeline with in-licensing of EVO570, a potential best-in-class oral VAV-1 molecular glue degrader |
| 05 Nov 2026 |
8-K: Regulation FD Disclosure
Management to discuss the in-licensing of EVO570, an oral VAV1-directed molecular glue degrader |
| 04 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 4, 2026, by and among Evommune, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an... |
| 01 Oct 2026 |
8-K: Regulation FD Disclosure
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress |
| 23 Sep 2026 |
8-K: Regulation FD Disclosure
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
Evommune Corporate Presentation September 2026 © Evommune, Inc. |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
‑ Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 |
| 30 Jul 2026 |
8-K: Regulation FD Disclosure
‑ MRGPRX2 receptor expressed in human trigeminal neurons and meningeal mast cells, the two key disease-relevant tissues in migraine biology |
| 29 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
‑ Trial did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks |
| 02 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 2, 2026, Evommune, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the following two proposa... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
‑ Phase 2b top-line data from EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) on track for June 2026 and 3Q26, respectively, with enrollment complete in both trials |
| 13 Apr 2026 |
8-K: Regulation FD Disclosure
Forward-Looking Statements © Evommune, Inc. This presentation has been prepared by Evommune, Inc. (“we”, “us” or “our”). Statements contained in this presentation regarding matters that are not historical facts are “forward-looking state... |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) |
| 13 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 12, 2026, by and among Evommune, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, a... |
| 10 Feb 2026 |
8-K: Regulation FD Disclosure
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis |
| 11 Dec 2025 |
8-K: Results of Operations and Financial Condition
- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) |
| 07 Nov 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Evommune, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: |
Loading...